Population Pharmacokinetics and Exposure-Response Analyses of Vepdegestrant, a First-in-Class PROteolysis-TArgeting Chimera Estrogen Receptor Degrader.

Veppanu (vepdegestrant) - Rigel Pharmaceuticals

http://www.ncbi.nlm.nih.gov/pubmed/42572241

Brian Jermain; Derek Z Yang; Hechuan Wang; Joanna C Masters; Kimberly C Lee; Lana Tran; Weiwei Tan; Yuanyuan Zhang

Aug 11, 2026